Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biomark DiagnosticsBMKDF 24 FCF Yield % is -1.86 as of Aug. 01, 2026. GuruFocus rates BMKDF with a GF Score™ of 24/100. The stock has 4 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Biomark Diagnostics ranks worse than 57.75% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Biomark Diagnostics FCF Yield % Related Terms
Biomark Diagnostics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Biomark Diagnostics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Biomark Diagnostics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomark Diagnostics FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Biomark Diagnostics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomark Diagnostics (BMKDF) has a FCF Yield % of -1.86 as of Aug. 01, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Biomark Diagnostics and its competitors. According to the industry distribution chart, Biomark Diagnostics ranks #123 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 57.7%.
Is Biomark Diagnostics' FCF Yield % too high?
Biomark Diagnostics' current FCF Yield % is -1.86. Based on the distribution chart, Biomark Diagnostics ranks #123 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Biomark Diagnostics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Biomark Diagnostics' FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biomark Diagnostics ranks #123 out of 213 companies for FCF Yield %. This places Biomark Diagnostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Biomark Diagnostics and its competitors. Biomark Diagnostics's current FCF Yield % is -1.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomark Diagnostics stock overvalued right now?
Biomark Diagnostics (BMKDF) has a current FCF Yield % of -1.86. The current FCF Yield % is -1.86. Biomark Diagnostics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Biomark Diagnostics (BMKDF), the current FCF Yield % is -1.86 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
24GF Score
Get the complete analysis for BMKDF
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMKDF has been successfully added to your 
